Approval Advice from EMA to EU for the Use of AstraZeneca Vaccine

Approval advice was given from EMA to the EU for the use of the AstraZeneca vaccine produced to combat the coronavirus epidemic.

Approval recommendation was given from EMA to EU for the use of AstraZeneca vaccine. The European Union's drug regulator, the European Medicines Agency (EMA), has recommended that AstraZeneca to be approved for the use as the vaccine developed for the treatment of coronavirus. After the approval of the European Union Commission, the AstraZeneca vaccine will be registered as the third coronavirus vaccine that can be used in the EU. In the statement made by the EMA, it was stated that the coronavirus vaccine can be applied to those over the age of 18. It was noted that the results of 4 clinical trials in Brazil, England and South Africa, in which 24 thousand people participated, were examined, and it was noted that the vaccine was safe and effective in 18-year-olds. In the statement, it was also noted that the AstraZeneca vaccine, which was administered as two doses between 4 and 12 weeks, was 60 percent effective in clinical trials. In the statement, it was stated that most of the participants in the studies were between 18 and 55 years old, while it was noted that there is currently not enough data to show how well the coronavirus vaccine works in people over the age of 55. In the statement on the subject, following took place, "However, protection is expected as an immune response is seen in this age group. Based on experience from other vaccines, EMA experts consider that the vaccine can be used in older people." In the European Union, the vaccines developed by BioNTech-Pfizer and Moderna were approved for use previously.